Ignite Creation Date:
2024-05-06 @ 12:53 AM
Last Modification Date:
2024-10-26 @ 10:56 AM
Study NCT ID:
NCT01681186
Status:
COMPLETED
Last Update Posted:
2019-10-21
First Post:
2012-09-04
Brief Title:
A Study of LY2940680 in Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study involves 2 parts Part A and Part B The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants Part A will involve two groups of participants each taking up to two single doses of LY2940680 at different dose levels There is a minimum 14 day washout period between each of the participants doses The purpose of Part B is to study how much of the study drug in capsule or tablet form gets into the bloodstream and how long the body takes to get rid of it In addition the effect of food and a proton pump inhibitor PPI on LY2940680 will be studied Part B will involve one group of participants who will take four single doses of 100 milligrams mg LY2940680 There is a minimum 7 day washout period between doses Participants may only enroll in one part Screening is required within 28 days prior to the start of the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| I4J-MC-HHBG | OTHER | Eli Lilly and Company | None |